ORIX Growth Capital today announced that it has completed a growth capital investment in Anaconda, one of the world’s most recognized data science companies.
“Anaconda provides a core platform for data science and machine learning. Their ability to provide powerful open-source capabilities that can scale to Enterprise-grade collaboration and project management further helps customers accelerate model development and streamline mission-critical workflows,” said David Orlandella, Managing Director and Healthcare lead for ORIX Growth Capital. “We are impressed with Anaconda’s team and their deep industry expertise. Their customer base of global blue-chip and Fortune 100 companies is a testament to their leading market position in the data science community. We are excited to partner with Anaconda to support their strong momentum and growth.”
“We are pleased to announce this additional investment as Anaconda continues to grow our customer base, innovate in our enterprise product, and champion the value of open-source data science. Enterprises in a wide range of industries are embracing the potential of machine learning while also realizing the challenges of operationalizing it at scale, and we offer them an effective platform to turn data science output into real business value,” said Scott Collison, CEO of Anaconda.
All trademarks and logos noted are property of their respective owners and no endorsement or association of or with ORIX USA or its affiliates is intended or implied.